Fig. 5

Progression free survival in patients treated by RD triplets by the presence of extraosseous disease 

A – DRD regimen (daratumumab, lenalidomide, dexamethasone). B – KRD regimen (carfilzomib, lenalidomide, dexamethasone). C – E-IRD regimen („early “ ixazomib, lenalidomide, dexamethasone). L-IRD regimen not shown (number of patients with presence of extraosseous disease was below the selected limit)